Cost Plus

SS-31 (Elamipretide) is a mitochondria-targeting peptide developed to improve mitochondrial function and reduce oxidative stress. It is a synthetic tetrapeptide that penetrates cell membranes and localizes to the inner mitochondrial membrane, where it interacts with cardiolipin, a key phospholipid essential for mitochondrial stability and function.
Mechanism of ActionElamipretide works by:
Binding to cardiolipin to stabilize mitochondrial membranes
Reducing mitochondrial reactive oxygen species (ROS) production
Enhancing ATP (energy) production
Improving electron transport chain efficiency
Potential ApplicationsDue to its ability to restore mitochondrial function, SS-31 is being studied for various diseases, including:
Mitochondrial Myopathies (e.g., Barth syndrome, MELAS syndrome)
Cardiovascular Diseases (e.g., heart failure, ischemia-reperfusion injury)
Neurodegenerative Diseases (e.g., Alzheimer’s, Parkinson’s)
Age-related Conditions (e.g., frailty, sarcopenia)

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that stimulates the secretion of growth hormone (GH) from the pituitary gland. It belongs to the class of growth hormone secretagogues (GHS) and works by mimicking the natural ghrelin hormone, which binds to the ghrelin receptor (GHS-R1a) in the hypothalamus.
Mechanism of ActionIncreases Growth Hormone (GH) Release: GHRP-6 stimulates GH secretion, leading to muscle growth, fat loss, and improved recovery.
Stimulates Ghrelin Receptor: It enhances appetite by mimicking ghrelin, the "hunger hormone."
Suppresses Somatostatin: Somatostatin inhibits GH release, but GHRP-6 helps block its effects, allowing more GH to be secreted.

Cyclophosphamide 500 mg Injection, also known as Cyclophosphamide Injection, is a chemotherapy medication primarily used in the treatment of cancer and autoimmune diseases. It belongs to the class of drugs known as alkylating agents, which work by interfering with the DNA replication process in rapidly dividing cells. This mechanism helps to target and destroy cancerous cells, but it can also affect healthy cells, leading to side effects.
Indications: Cyclophosphamide is indicated for the treatment of various types of cancers, including:
    Breast cancer    Non-Hodgkin lymphoma    Hodgkin lymphoma    Leukemia (both chronic and acute)    Ovarian cancer    Multiple myeloma    Sarcoma
It is also used in treating non-cancerous conditions such as autoimmune diseases, particularly:
    Systemic lupus erythematosus (SLE)    Nephrotic syndrome    Vasculitis    Rheumatoid arthritis
Cyclophosphamide may be used alone or in combination with other chemotherapy agents, depending on the type and stage of cancer, or the autoimmune condition being treated.
Mechanism of Action: Cyclophosphamide functions by being metabolized in the liver into active compounds that interfere with DNA synthesis in cells. These compounds form cross-links within the DNA, preventing it from uncoiling and replicating. This results in the inability of cancer cells or abnormal immune cells to divide and proliferate. The drug's action is not selective, and it can affect both cancerous and healthy cells, particularly those that rapidly divide, such as hair follicles, bone marrow, and the lining of the gastrointestinal tract.
Administration: Cyclophosphamide 500 mg Injection is usually administered intravenously (IV) in a healthcare setting, such as a hospital or clinic, under the supervision of a healthcare professional. The dosage and frequency of administration depend on the specific medical condition being treated, the patient's response to the drug, and any other underlying health issues. Cyclophosphamide may be given as a single dose or as part of a multi-dose regimen. It is crucial for the healthcare provider to monitor the patient closely during and after administration to manage potential side effects.
Side Effects: Like many chemotherapy drugs, Cyclophosphamide has a range of potential side effects, some of which can be serious. Common side effects include:
    Nausea and vomiting    Hair loss (alopecia)    Fatigue    Decreased blood cell counts (leading to increased risk of infections, bleeding, or anemia)    Mouth sores    Diarrhea or constipation    Changes in appetite
Serious side effects may include:
    Hemorrhagic cystitis (bladder inflammation and bleeding), which can be managed with hydration and mesna, a protective drug    Heart damage (cardiotoxicity) in high doses    Liver or kidney damage    Secondary cancers, including leukemia    Infertility, especially with long-term use or high doses
Patients undergoing Cyclophosphamide treatment will be monitored for these and other potential complications, and supportive therapies may be provided to alleviate symptoms.
Precautions and Contraindications: Before receiving Cyclophosphamide, patients must inform their doctor of any allergies to the drug or any other medications, as well as any pre-existing health conditions such as liver disease, kidney disease, heart conditions, or infections. Cyclophosphamide should not be used during pregnancy due to its potential teratogenic effects, and breastfeeding is not recommended during treatment.

Liraglutide injection is a medication used to manage type 2 diabetes and, in some cases, for weight management in individuals who are obese or overweight. Liraglutide is a GLP-1 receptor agonist (glucagon-like peptide-1), which mimics the action of the naturally occurring hormone GLP-1 in the body. This hormone plays a critical role in regulating blood sugar levels, appetite, and insulin secretion.Mechanism of Action
Liraglutide works by mimicking GLP-1, a hormone that is released by the intestines in response to food intake. GLP-1 stimulates the pancreas to release insulin in response to meals, which helps lower blood sugar levels.By mimicking these effects, Liraglutide helps to:
    Lower blood sugar: It enhances insulin secretion when blood glucose levels are high, thus improving glycemic control.    Promote weight loss: Through its action on appetite regulation and delayed gastric emptying, Liraglutide can help patients reduce food intake, contributing to weight loss.    Reduce the risk of cardiovascular events: Liraglutide has been shown to reduce the risk of major cardiovascular events in patients with type 2 diabetes who have heart disease or are at high risk.
Primary Uses
    Type 2 Diabetes: Liraglutide is approved for the management of type 2 diabetes, typically in conjunction with diet and exercise. It helps improve blood sugar control by stimulating insulin release, inhibiting glucagon production, and slowing gastric emptying. It can be used alone or in combination with other oral diabetes medications such as metformin or sulfonylureas.
    Weight Loss: Liraglutide is also approved for use in overweight and obese individuals, under the brand name Saxenda. It is used as part of a comprehensive weight management plan, alongside a reduced-calorie diet and increased physical activity. Liraglutide has been shown to help reduce body weight by decreasing appetite and increasing feelings of fullness.
Dosage and Administration
Liraglutide is administered as a subcutaneous injection, usually in the abdomen, thigh, or upper arm. The dosage and frequency vary depending on the condition being treated.
    For type 2 diabetes (Victoza): The typical starting dose is 0.6 mg once daily, which may be increased gradually based on tolerance to a maximum dose of 1.8 mg daily. It is injected at the same time each day, with or without meals.    For weight management (Saxenda): The initial dose is typically 0.6 mg daily, which is gradually increased until a target dose of 3.0 mg daily is reached. It is administered once a day, ideally at the same time each day.
The injection is easy to administer, and patients are usually instructed on how to use a pre-filled pen for injection. It is important to follow the prescribed dose and to gradually increase the dosage to minimize potential side effects.Side Effects and Precautions
While Liraglutide is generally well tolerated, it can cause some side effects, including:
    Gastrointestinal issues: Nausea, vomiting, diarrhea, constipation, and abdominal pain are common, especially when first starting the medication. These symptoms often subside as the body adjusts.    Hypoglycemia: Liraglutide can increase insulin release, which may cause low blood sugar, especially if used with other diabetes medications that increase insulin, such as sulfonylureas or insulin.    Pancreatitis: Although rare, there is a risk of pancreatitis (inflammation of the pancreas) with Liraglutide. Symptoms include severe abdominal pain, nausea, and vomiting.    Kidney problems: In rare cases, Liraglutide may cause kidney issues, particularly in patients who are dehydrated or have pre-existing kidney disease.